Trial Profile

A Phase I/II Open-Label Trial of CPI-613 (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 26 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Devimistat (Primary) ; Hydroxychloroquine (Primary)
Indications Clear cell sarcoma; Ewing's sarcoma; Sarcoma; Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms APOLLO 613
Sponsors Cornerstone Pharmaceuticals Inc

22 May 2023 Status changed from recruiting to completed.
10 Nov 2022 Planned number of patients changed from 65 to 59.
07 Jun 2022 Planned number of patients changed from 47 to 65, as per Trial design, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com